CRC
AERI

Curi RMB Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Curi RMB Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-52,070
Closed -$1.26M – 806
2019
Q4 		$1.26M Sell
52,070
-41,110
-44% -$851K 0.04% 334
2019
Q3 		$1.79M Buy
+93,180
New +$2.13M 0.05% 312

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Curi RMB Capital's AERI Position: Q1 2020 in Review

Curi RMB Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2020, closing a stake of 52,070 shares — an estimated $1.26M sold.

Curi RMB Capital first reported a position in AERI in Q3 2019 and held it in 2 quarters. The position peaked at $1.79M in Q3 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q1 2020.

  • Curi RMB Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Curi RMB Capital sold 52,070 Aerie Pharmaceuticals shares in Q1 2020, an estimated $1.26M.
  • Curi RMB Capital first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Curi RMB Capital's Aerie Pharmaceuticals position peaked at $1.79M in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2020.

Based on Curi RMB Capital's 13F filing for Q1 2020, filed 11 May 2020.